Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report
Abstract Background Severe epistaxis is often difficult to control in patients with hereditary hemorrhagic telangiectasia (HHT). Propranolol has been shown to have antiangiogenic properties in vitro and in vivo and is commonly used to treat hemangiomas. We present our experience with topical nasal p...
Main Authors: | Meir Mei-Zahav, Hannah Blau, Elchanan Bruckheimer, Eyal Zur, Neta Goldschmidt |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-10-01
|
Series: | Journal of Otolaryngology - Head and Neck Surgery |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40463-017-0235-x |
Similar Items
-
Topical Propranolol Improves Epistaxis Control in Hereditary Hemorrhagic Telangiectasia (HHT): A Randomized Double-Blind Placebo-Controlled Trial
by: Meir Mei-Zahav, et al.
Published: (2020-09-01) -
Prospective pilot study of Floseal® for the treatment of anterior epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT)
by: John M. Lee, et al.
Published: (2019-10-01) -
Hereditary Hemorrhagic Telangiectasia: Genetics, Pathophysiology, Diagnosis, and Management
by: Adrian Viteri-Noël, et al.
Published: (2022-09-01) -
Thalidomide for the Management of Bleeding Episodes in Patients with Hereditary Hemorrhagic Telangiectasia: Effects on Epistaxis Severity Score and Quality of Life
by: Mehmet Baysal, et al.
Published: (2019-02-01) -
Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis
by: Huimin Chen, et al.
Published: (2023-12-01)